# OnCo record irae-ocular (protocol). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/protocols/irae-ocular/>
  a schema:MedicalGuideline ;
  onco:kind "protocol" ;
  schema:identifier "irae-ocular" ;
  schema:name "Eye side effects of checkpoint inhibitors: dry eye, uveitis and optic neuritis"@en ;
  schema:alternateName "checkpoint inhibitor uveitis"@en, "ocular irAEs"@en, "Eye-irAEs"@en, "immune-related uveitis"@en, "immune-related optic neuritis"@en, "immune-related dry eye disease"@en, "ophthalmic immune-related adverse events"@en ;
  schema:description "Immunotherapy can occasionally cause dry, gritty eyes or inflammation inside the eye (uveitis), and rarely of the nerve to the eye. Red or painful eyes, sensitivity to light, floaters, blurred or double vision, or drooping eyelids should be reported so an eye specialist can see you. Most is treated with eye drops and immunotherapy usually continues; sudden loss of vision is an emergency."@en ;
  schema:url <https://onco.cc/protocols/irae-ocular/> ;
  schema:dateModified "2026-11-11"^^xsd:date ;
  onco:tag "protocol", "irae", "ophthalmology" ;
  onco:related <https://onco.cc/protocols/irae-neurological/>, <https://onco.cc/protocols/irae-thyroid/>, <https://onco.cc/protocols/irae-hypophysitis-adrenal/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/cemiplimab/>, <https://onco.cc/drugs/tremelimumab/>, <https://onco.cc/drugs/avelumab/>, <https://onco.cc/drugs/dostarlimab/>, <https://onco.cc/drugs/methylprednisolone/> ;
  onco:institutions <https://onco.cc/institutions/sitc/>, <https://onco.cc/institutions/asco/>, <https://onco.cc/institutions/esmo/> ;
  onco:terms <https://onco.cc/terms/irae/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-asco-irae-guideline-jco-2021/> .